

cell-fusion-based phenotypic HIV-1 tropism assay. *J Int AIDS Soc*, 16: 18723, 2013.

- 2) Nomura S, Hosoya N, Brumme ZL, Brockman MA, Kikuchi T, Koga M, Nakamura H, Koibuchi T, Fujii T, Carlson JM, Heckerman D, Kawana-Tachikawa A, Iwamoto A, Miura T. Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan. *J Virol*, 87: 1465-1476, 2013.

井上 誠

- 1) Iwamoto N, Takahashi N, Seki S, Nomura T, Yamamoto H, Inoue M, Shu T, Naruse TK, Kimura A, Matano T. Control of Simian Immunodeficiency Virus Replication by Vaccine-Induced Gag- and Vif-Specific CD8+ T Cells. *J Virol*, 88: 425-33, 2014.
- 2) Takahashi N, Nomura T, Takahara Y, Yamamoto H, Shiino T, Takeda A, Inoue M, Iida A, Hara H, Shu T, Hasegawa M, Sakawaki H, Miura T, Igarashi T, Koyanagi Y, Naruse TK, Kimura A, Matano T. A novel protective MHC-I haplotype not associated with dominant Gag-specific CD8+ T-cell responses in SIVmac239 infection of Burmese rhesus macaques. *PLoS One*. 8: e54300, 2013.

鳴海 哲夫

- 1) Hashimoto C, Narumi T, Yoshimura K, Igarashi T, Matsushita S, Tamamura H, et al. A CD4 Mimic as an HIV Entry Inhibitors: Pharmacokinetics. *Bioorg Med Chem*, 21: 7884-7889, 2013.
- 2) Narumi T, Tamamura H, Matsushita S, Igarashi T, et al. Generation of a Replication-competent Simian-human Immunodeficiency Virus, the Neutralisation Sensitivity of Which can be Enhanced in the Presence of a Small Molecule CD4 Mimic. *J Gen Virol*, 94: 2710-2716, 2013.
- 3) Nomura W, Narumi T, Yamamoto N, Murakami T, Tamamura H, et al. CXCR4-derived Synthetic Peptides Inducing Anti-HIV-1 Antibodies. *Bioorg Med Chem*, 21: 6878-6885, 2013
- 4) Hashimoto C, Nomura W, Narumi T, Yamamoto N, Murakami T, Tamamura H, et al. Anti-HIV-1 Peptide Derivatives Based on the HIV-1 Co-receptor CXCR4. *Chem Med Chem*, 8:1668-1672, 2013.
- 5) Nomura W, Aikawa H, Narumi T, Yamamoto N, Murakami T, Tamamura H, et al. Cell-Permeable Stapled Peptides Based on HIV-1 Integrase Inhibitors Derived from HIV-1 Gene Products. *ACS Chem Biol*, 8: 2235-2244, 2013.
- 6) Narumi T, Arai H, Yoshimura K, Harada S, Hirota Y, Ohashi N, Hashimoto C, Nomura W, Matsushita S, Tamamura H. CD4 Mimics as HIV Entry Inhibitors: Lead Optimization Studies of the Aromatic Substituents. *Bioorg Med Chem*, 21: 2518-2526, 2013.
- 7) Narumi T, Aikawa H, Tanaka T, Hashimoto C, Ohashi N, Nomura W,

Kobayakawa T, Takano H, Hirota Y, Murakami T, Yamamoto N, Tamamura H. Low Molecular Weight CXCR4 Ligands with Variable Spacers. *Chem Med Chem*, 8:118-124, 2013.

桑田 岳夫

- 1) Kuwata T, Takaki K, Enomoto I, Yoshimura K, Matsushita S. Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. *Frontiers in Microbiology/Virology*, 4: 1-7, 2013.
- 2) Kuwata T, Takaki K, Yoshimura K, Enomoto I, Wu F, Ourmanov KI, Hirsch VM, Yokoyama M, Sato H, Matsushita S. Conformational Epitope Consisting of the V3 and V4 Loops as a Target for Potent and Broad Neutralization of Simian Immunodeficiency Viruses. *J Virol*, 87: 5424-5436, 2013.

IV. 研究成果の刊行物・別刷

Short
CommunicationGeneration of a replication-competent
simian–human immunodeficiency virus, the
neutralization sensitivity of which can be enhanced
in the presence of a small-molecule CD4 mimicHiroyuki Otsuki,¹ Takayuki Hishiki,¹ Tomoyuki Miura,¹ Chie Hashimoto,²
Tetsuo Narumi,² Hirokazu Tamamura,² Kazuhisa Yoshimura,³
Shuzo Matsushita⁴ and Tatsuhiko Igarashi¹

Correspondence

Tatsuhiko Igarashi

tigarash@virus.kyoto-u.ac.jp

¹Laboratory of Primate Model, Experimental Research Center for Infectious Diseases,
Institute for Virus Research, Kyoto University, Kyoto 606-8507, Japan²Department of Medicinal Chemistry, Institute of Biomaterials and Bioengineering,
Tokyo Medical and Dental University, Tokyo 101-0062, Japan³AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan⁴Division of Clinical Retrovirology and Infectious Diseases, Center for AIDS Research,
Kumamoto University, Kumamoto 860-0811, Japan

Simian–human immunodeficiency virus (SHIV) carrying the envelope from the clade B clinical human immunodeficiency virus type 1 (HIV-1) isolate MNA, designated SHIV MNA, was generated through intracellular homologous recombination. SHIV MNA inherited biological properties from the parental HIV-1, including CCR5 co-receptor preference, resistance to neutralization by the anti-V3 loop mAb KD-247 and loss of resistance in the presence of the CD4-mimic small-molecule YYA-021. SHIV MNA showed productive replication in rhesus macaque PBMCs. Experimental infection of a rhesus macaque with SHIV MNA caused a transient but high titre of plasma viral RNA and a moderate antibody response. Immunoglobulin in the plasma at 24 weeks post-infection was capable of neutralizing SHIV MNA in the presence but not in the absence of YYA-021. SHIV MNA could serve a model for development of novel therapeutic interventions based on CD4-mimic-mediated conversion of envelope protein susceptible to antibody neutralization.

Received 29 May 2013

Accepted 10 September 2013

Control of primate lentiviral infection by antibodies directed against viral envelope protein is theoretically feasible. This was confirmed by the successful protection of macaque monkeys from challenge inoculation with simian–human immunodeficiency virus (SHIV) carrying an envelope protein (Env). Env was derived from a laboratory strain of human immunodeficiency virus type 1 (HIV-1) through the passive immunization of neutralizing mAbs directed against HIV-1 (Mascola *et al.*, 2000; Nishimura *et al.*, 2003). This neutralization is consistent with the results normally seen in cell culture systems.

In contrast, clinical isolates of HIV-1 that have not been subjected to extensive passage in T-cell lines are generally resistant to antibody-mediated neutralization (Moore *et al.*, 1995). It has been shown that virus in infected individuals is under selective pressure to develop a variety of means to

evade attack by neutralizing antibodies, including sequence variation, glycosylation, tertiary structural shielding formed by the Env trimer and the rapid kinetics of conformational changes of Env, which affect fusion between the viral envelope and the plasma membrane of target cells (Kong & Sattentau, 2012). Although four major neutralizing epitopes have been identified in HIV-1 Env (i.e. the V1/V2 loop, the glycan-V3 site and CD4-binding site of gp120, and the membrane-proximal external region of gp41), for reasons that are as yet unclear few reports of antibodies directed against these epitopes capable of neutralizing a broad range of isolates have been published (Kwong & Mascola, 2012). High titres of antibodies directed against the V3 loop are elicited in individuals during the early phase of HIV-1 infection, but these are incapable of neutralizing the virus because the epitope in functional Env trimer is probably shielded from the antibody (Davis *et al.*, 2009b). Therefore, it is necessary to develop a means of rendering these epitopes accessible to

One supplementary table and five supplementary figures are available with the online version of this paper.

the antibodies, to make antibody-mediated suppression of HIV-1 a valid therapeutic option.

It has been reported that neutralization mediated by antibodies directed against the V3 loop (Lusso *et al.*, 2005) or CD4-induced epitope (CD4i) (Thali *et al.*, 1993) can be enhanced in the presence of soluble CD4 (sCD4). It is known that the interaction of Env with sCD4 drives a conformational change of the viral protein and makes the cryptic/occult epitopes accessible to these antibodies (Wyatt *et al.*, 1998). Small molecules that emulate sCD4 for its interaction and subsequent induction of conformational change of Env may be employed to intensify antibody-mediated interventions against HIV-1 infection. Compounds with the above-mentioned properties (i.e. NBD-556 and NBD-557) have been reported previously (Zhao *et al.*, 2005). NBD-556 has been shown in cell culture to interact with the CD4-binding pocket to induce a conformational change in gp120 (Madani *et al.*, 2008) and enhance exposure of the Env of primary HIV-1 isolates to neutralizing epitopes (Yoshimura *et al.*, 2010).

The present study was performed to evaluate small-molecule CD4-mimic-based enhancement of antibody-mediated virus neutralization, in the context of virus infection *in vivo*. The SHIV/macaque monkey model of AIDS is particularly suitable for such studies, as SHIV carries the HIV-1 Env and the neutralization sensitivity of SHIV is comparable to that of the parental HIV-1 (Shibata & Adachi, 1992).

As NBD-556, unlike sCD4, inhibits infection with select HIV-1 isolates (Yoshimura *et al.*, 2010), we generated a new SHIV strain carrying Env, the sensitivity of which to antibody-mediated neutralization is enhanced in the presence of a CD4 mimic. An HIV-1 isolate (MNA), previously designated primary isolate HIV-1 Pt.3, was used as the source of Env, as the viral protein has been reported to interact with NBD-556 (Yoshimura *et al.*, 2010). While the virus belongs to a distinct subset of HIV-1 isolates, as mentioned above, it has also been reported to utilize the CCR5 molecule to gain entry into target cells, a property that is shared by the majority of HIV-1 strains (Yoshimura *et al.*, 2010). A mAb directed against the tip of the V3 loop (GPGR motif), KD-247 (Eda *et al.*, 2006), was employed to assess this concept, as HIV-1 MNA is resistant to KD-247-mediated neutralization, despite carrying the exact epitope sequence in the tip of the V3 loop, and is converted to being sensitive to the antibody by NBD-556 in a dose-dependent manner (Yoshimura *et al.*, 2010).

First, we reproduced the results of Yoshimura *et al.* (2010) using a neutralization assay employing TZM-bl cells (Platt *et al.*, 1998), obtained from the National Institutes of Health (NIH) AIDS Reagent Program (Fig. S1, available in JGV Online). The virus was resistant to KD-247, as described previously, and required almost $50 \mu\text{g ml}^{-1}$ of the antibody to achieve 50% neutralization in our assay. However, the observed resistance was eliminated in the presence of $2 \mu\text{M}$ NBD-556; 50% neutralization was

achieved in the presence of $\sim 0.1 \mu\text{g KD-247 ml}^{-1}$, corresponding to 1/500 of the amount of the antibody to achieve the same degree of neutralization in the absence of the CD4 mimic.

With reproduction of the properties of HIV-1 MNA Env, we generated an SHIV strain carrying Env through intracellular homologous recombination, as described previously (Fujita *et al.*, 2013) with minor modifications (Fig. S2). DNA fragments representing the 5' and 3' ends of the SHIV genome (fragments I and II, respectively) were amplified by PCR from the proviral DNA plasmid SHIV KS661. A DNA fragment containing *env* (fragment III) was amplified from cDNA of the HIV-1 MNA genome, which was prepared from virus particles (virion-associated RNA) in the culture supernatant of PM1/CCR5 cells (Yusa *et al.*, 2005) infected with the virus. The PCR primers used are listed in Table S1. Using a FuGENE HD transfection reagent, lipofection was performed on the C8166-CCR5 cells (Shimizu *et al.*, 2006) to co-transfect them with $0.2 \mu\text{g}$ DNA. A cytopathic effect, presumably caused by the emerged recombinant virus, was observed on day 13 post-transfection. The emerged virus, designated SHIV MNA, carried the entire gp120 and three-quarters of gp41 from HIV-1 MNA Env (Fig. 1a). The rest of Env was from SHIV KS661, the Env of which was derived from HIV-1 89.6 (Shinohara *et al.*, 1999). The CD4 binding site, and the regions and elements that reportedly interact with NBD-556 (Madani *et al.*, 2008; Yoshimura *et al.*, 2010), are preserved in SHIV MNA Env (Fig. S3). The virus was replication competent in PM1/CCR5 cells (data not shown).

As HIV-1 MNA has been suggested to be a CCR5-utilizing virus, we were intrigued as to whether SHIV MNA inherited the trait from the parental virus. We subjected SHIV MNA and the parental HIV-1 MNA to a co-receptor usage assay as described previously (Nishimura *et al.*, 2010), with minor modifications (Fig. S4). As expected, SHIV MNA was shown to utilize CCR5 as an entry co-receptor.

We next assessed the neutralization profiles of SHIV MNA in comparison with the parental HIV-1 MNA, as described previously (Li *et al.*, 2005; Wei *et al.*, 2002). Both SHIV MNA and HIV-1 MNA showed essentially no neutralization by KD-247 up to $25 \mu\text{g ml}^{-1}$, and 50% neutralization was achieved at $50 \mu\text{g ml}^{-1}$ (Fig. 1b). As the CD4 mimic, we employed YYA-021, a compound generated and characterized through studies concerning the structure-activity relationships of small molecules (Narumi *et al.*, 2010, 2011, 2013; Yamada *et al.*, 2010). The compound was shown to be slightly less potent but to exhibit substantially lower toxicity than NBD-556, and was therefore a suitable choice for our purposes in future studies in animal models. SHIV MNA was resistant to neutralization by YYA-021 at all concentrations examined, except 25 and $50 \mu\text{M}$, and showed a neutralization profile almost identical to that of HIV-1 MNA (Fig. 1c). To further characterize the




Fig. 1. Genomic organization (a) and neutralization sensitivity (b–e) of SHIV MNA. (a) Grey shaded boxes represent genes derived from SIV239, open boxes those from HIV-1 89.6 and dark grey shaded boxes those from HIV-1 MNA. LTR, long terminal repeat. (b–e) Percentage neutralization was calculated as $100 \times [1 - (RLU.N - RLU.B) / (RLU.V - RLU.B)]$, where RLU is relative luciferase units; RLU.N is RLU in wells with cells, virus and KD-247 and/or YYA-021; RLU.V is RLU in wells with cells and virus; and RLU.B is RLU in wells with cells.

biological properties of SHIV MNA Env, a set of entry assays was conducted (Fig. S5). The *env* genes cloned from SHIV MNA and HIV-1 MNA were utilized to generate pseudotyped viruses. These pseudotypes were inoculated into TZM-bl cells in the presence of increasing amounts of NBD-556, YYA-021 or sCD4. A control group was derived

from another virus preparation pseudotyped with amphotropic murine leukemia virus (A-MLV) Env (Landau *et al.*, 1991). When the efficiency of entry was defined by intracellular luciferase activities, virtually no difference was observed between Envs of SHIV MNA and the parental HIV-1. Thus, SHIV MNA Env replicated in

C8166-CCR5 cells retained sensitivity to small-molecule CD4 mimics and sCD4 comparable to that of HIV-1 MNA.

We then examined whether the synergistic neutralization of HIV-1 MNA by KD-247 antibody in the presence of NBD-556 (Yoshimura *et al.*, 2010) would be reproduced when CD4 mimic was substituted by YYA-021. The synergistic neutralization effect of KD-247 and YYA-021 was reproduced in our experiments (Fig. 1d). At $50 \mu\text{g ml}^{-1}$, KD-247 barely achieved 50% neutralization of HIV-1 MNA but resulted in 50% neutralization at $<0.05 \mu\text{g ml}^{-1}$ in the presence of $20 \mu\text{M}$ of YYA-021.

Finally, to examine whether these two agents neutralized SHIV MNA in the same manner as the parental HIV-1, we conducted a neutralization assay with KD-247 in the

presence of increasing amounts of YYA-021 (0, 5, 10, 20 and $40 \mu\text{M}$) (Fig. 1e). The neutralization curve of KD-247 against SHIV MNA showed an upward shift as the concentration of YYA-021 increased (Fig. 1e), similar to the observations with HIV-1 (Fig. 1d), indicating augmentation of neutralization, and complete neutralization of both viruses was achieved at $20 \mu\text{M}$ YYA-021 (Fig. 1d, e). Based on these results, we concluded that the neutralization profile of SHIV MNA was comparable to that of HIV-1 MNA.

Reproduction of the neutralization characteristics of HIV-1 MNA in the newly generated SHIV prompted us to assess the ability of SHIV MNA to replicate in monkey cells. SHIV MNA, along with SIV239 and SHIV KS661, were normalized with infectious titres and inoculated into rhesus macaque PBMC preparations from four animals,




Fig. 2. Replication of SHIV MNA in rhesus macaque PBMCs (a) and *in vivo* (b). (a) M.o.i. was adjusted to 0.01 (TCID_{50} per cell). (b) Experimental infection of a rhesus macaque with SHIV MNA. SHIV MNA ($1.75 \times 10^5 \text{ TCID}_{50}$) was intravenously inoculated into a rhesus macaque, and the plasma viral RNA burden and circulating CD4⁺ T-lymphocytes were monitored.

as described previously (Fujita *et al.*, 2013) (Fig. 2a). SHIV KS661, a CXCR4-utilizing virus, replicated to the highest titres of all the viruses in all PBMC preparations. Compared with SHIV KS661, SIV239 replicated to lower titres. Under these experimental conditions, SHIV MNA showed productive replication in the cells with similar replication kinetics and peak titres to SIV239. Based on these results, we concluded that SHIV MNA was replication competent in primary monkey lymphocytes.

Productive replication of SHIV MNA in monkey PBMCs justified experimental infection of the virus *in vivo*. We inoculated 1.75×10^5 TCID₅₀ SHIV MNA intravenously into a rhesus macaque and monitored plasma viral RNA burden and circulating CD4⁺ T-lymphocyte levels (Fig. 2b). Plasma viral RNA burden reached a peak of 5.6×10^6 copies ml⁻¹ at 1 week post-infection (p.i.), and declined rapidly thereafter, reaching low levels of detection at 7 weeks p.i. (around 2.8×10^2 copies ml⁻¹). Circulating CD4⁺ T-cell numbers showed a transient decrease around 1 week p.i., rebounded around 3 weeks p.i. and stabilized around 70% of the pre-infection level from 4 weeks p.i. During the period of observation, the animal developed no obvious clinical manifestations related to lentivirus infection.

As SHIV MNA replicated *in vivo* without depleting helper T-cells, it was expected that the animal mounted an antiviral immune reaction. The production of antibody directed against Env was assessed by Western blotting, as described previously (Igarashi *et al.*, 1999). Purified Env protein (Advanced Biotechnologies) was used as the antigen (Fig. 3a). Anti-Env antibody was detected at 3 weeks p.i., and the level of antibody judged by the intensity of the band increased gradually with time.

We next examined whether the animal generated neutralizing antibodies against SHIV MNA. Because plasma samples from this specimen exhibited high background activity, IgG was purified from these samples collected on day 0 and in week 24 p.i. using protein G spin columns (GE Healthcare Japan). While the IgG from day 0 exhibited no neutralizing activity (Fig. 3b), as expected, the IgG collected at 24 weeks p.i. neutralized SHIV MNA, although a concentration $>100 \mu\text{g ml}^{-1}$ was required to suppress replication of 100 TCID₅₀ of the input virus (Fig. 3c).

We examined whether the observed marginal neutralization by the antibody could be enhanced by the presence of YYA-021. Upon addition of YYA-021 in the assay system, SHIV MNA became sensitive to IgG obtained at 24 weeks p.i. (Fig. 3c), while no enhancement was identified from day 0 (Fig. 3b).

In this study, we generated a replication-competent SHIV MNA strain carrying an Env resistant to the neutralizing mAb KD-247 but conditionally sensitive in the presence of the CD4 mimic YYA-021. As the observed neutralization characteristics were identical to those of HIV-1 MNA, which contributed the majority of the Env sequence to the chimera, the utility of the CD4 mimic as a means of enhancing antibody-mediated virus neutralization should be assessed in the context of infection *in vivo*. This concept could be tested during the acute phase of SHIV MNA infection, during which the virus undergoes substantial replication. To examine the feasibility of CD4-mimic-mediated enhancement of virus neutralization in the context of chronic infection, the conditions under which this type of intervention should be applied to HIV-1-infected patients in a clinical setting, the virus must be




Fig. 3. Antibody induced against SHIV MNA. (a) The anti-HIV-1 gp120 antibody response was assessed by Western blotting with plasma samples collected at the indicated times. An anti-HIV-1 V3 mAb, 4G10 (ascites diluted 1 : 100) (von Brunen *et al.*, 1993), obtained from the NIH AIDS Reagent Program, was used as a positive control (lane anti-V3). (b, c) Neutralization of SHIV MNA with IgG purified from plasma of the infected rhesus macaque (day 0 and week 24 p.i.) with 20 μM YYA-021 or without YYA-021.

modified to sustain productive replication for a longer period. SHIV MNA in the present form does not fulfil this requirement. It is possible that animal-to-animal passage could increase the fitness of the virus in monkeys.

This study demonstrated that a CD4 mimic could modulate viral Env protein to be more susceptible to neutralization by less potent antibodies generated in the context of infection. During the early phase of infection, patients mount high titres of non-neutralizing antibodies directed against the V3 loop (Davis *et al.*, 2009a). Patients with HIV-1 clade C generate anti-Env antibodies, including anti-CD4i antibodies, with poor neutralizing activity against recent infection (Gray *et al.*, 2007). It is possible that the CD4 mimic YYA-021 causes a conformational change in SHIV MNA Env, which renders sequestered epitope(s) accessible to potentially neutralizing IgG, such as ones directed against the V3 loop and CD4i.

The current study extended the previous study by Yoshimura *et al.* (2010) and used HIV-1 MNA belonging to clade B to generate a new SHIV strain carrying Env. The neutralization sensitivity of this strain is characteristically augmented in the presence of a small-molecule CD4 mimic. Similar observations by Decker *et al.* (2005) showed that infections of a wide range of HIV-1 strains of multiple clades or circulating recombinant forms elicit high titres of anti-CD4i antibodies. These anti-CD4i antibodies neutralize viruses as divergent as HIV-2 in the presence of sCD4 (Decker *et al.*, 2005). Taking these observations into account, small-molecule CD4 mimics such as YYA-021 could potentially enhance the neutralization activity of the antibodies directed against autologous viruses belonging not only to clade B but also to multiple HIV-1 strains of various clades and possibly even HIV-2. Our results pave the way for a novel therapeutic intervention based on administration of CD4 mimics to patients with HIV to facilitate control of the virus by their own antibodies.

Acknowledgements

Thanks should be given to: Drs Julie Strizki and Paul Zavodny of the Schering-Plough Research Institute, Kenilworth, NJ, USA, for providing AD101; the NIH AIDS Research & Reference Reagent Program for providing TZM-bl cells, SV-A-MLV-env, 4G10 and soluble CD4; the Chemo-Sero-Therapeutic Research Institute, Kaketsuken, Japan, for providing mAb KD-247; former and current members of the Igarashi Laboratory for discussion and support. This work was supported by a Research on HIV/AIDS grant from the Ministry of Health, Labor and Welfare of Japan (H22-AIDS Research-007 and H24-AIDS Research-008) and by a Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science (23300156).

References

Davis, K. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Kutsch, O., Morris, L., Salomon, A., Pinter, A., Hoxie, J. A. & other authors (2009a). Human immunodeficiency virus type 2 (HIV-2)/HIV-1

envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. *J Virol* **83**, 1240–1259.

Davis, K. L., Gray, E. S., Moore, P. L., Decker, J. M., Salomon, A., Montefiori, D. C., Graham, B. S., Keefer, M. C., Pinter, A. & other authors (2009b). High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. *Virology* **387**, 414–426.

Decker, J. M., Bibollet-Ruche, F., Wei, X., Wang, S., Levy, D. N., Wang, W., Delaporte, E., Peeters, M., Derdeyn, C. A. & other authors (2005). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. *J Exp Med* **201**, 1407–1419.

Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H. & other authors (2006). Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. *J Virol* **80**, 5552–5562.

Fujita, Y., Otsuki, H., Watanabe, Y., Yasui, M., Kobayashi, T., Miura, T. & Igarashi, T. (2013). Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying env from subtype C clinical isolate through intracellular homologous recombination. *Virology* **436**, 100–111.

Gray, E. S., Moore, P. L., Choge, I. A., Decker, J. M., Bibollet-Ruche, F., Li, H., Leseka, N., Treurnicht, F., Mlisana, K. & other authors (2007). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. *J Virol* **81**, 6187–6196.

Igarashi, T., Endo, Y., Englund, G., Sadjadpour, R., Matano, T., Buckler, C., Buckler-White, A., Plishka, R., Theodore, T. & other authors (1999). Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. *Proc Natl Acad Sci U S A* **96**, 14049–14054.

Kong, L. & Sattentau, Q. J. (2012). Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. *J AIDS Clin Res* **S8**, 3.

Kwong, P. D. & Mascola, J. R. (2012). Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. *Immunity* **37**, 412–425.

Landau, N. R., Page, K. A. & Littman, D. R. (1991). Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. *J Virol* **65**, 162–169.

Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors (2005). Human immunodeficiency virus type 1 *env* clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. *J Virol* **79**, 10108–10125.

Lusso, P., Earl, P. L., Sironi, F., Santoro, F., Ripamonti, C., Scarlatti, G., Longhi, R., Berger, E. A. & Burastero, S. E. (2005). Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. *J Virol* **79**, 6957–6968.

Madani, N., Schön, A., Princiotto, A. M., Lalonde, J. M., Courter, J. R., Soeta, T., Ng, D., Wang, L., Brower, E. T. & other authors (2008). Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. *Structure* **16**, 1689–1701.

Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S. & other authors (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. *Nat Med* **6**, 207–210.

Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R. & Ho, D. D. (1995).


- Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. *J Virol* **69**, 101–109.
- Narumi, T., Ochiai, C., Yoshimura, K., Harada, S., Tanaka, T., Nomura, W., Arai, H., Ozaki, T., Ohashi, N. & other authors (2010). CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. *Bioorg Med Chem Lett* **20**, 5853–5858.
- Narumi, T., Arai, H., Yoshimura, K., Harada, S., Nomura, W., Matsushita, S. & Tamamura, H. (2011). Small molecular CD4 mimics as HIV entry inhibitors. *Bioorg Med Chem* **19**, 6735–6742.
- Narumi, T., Arai, H., Yoshimura, K., Harada, S., Hirota, Y., Ohashi, N., Hashimoto, C., Nomura, W., Matsushita, S. & Tamamura, H. (2013). CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. *Bioorg Med Chem* **21**, 2518–2526.
- Nishimura, Y., Igarashi, T., Haigwood, N. L., Sadjadpour, R., Donau, O. K., Buckler, C., Plishka, R. J., Buckler-White, A. & Martin, M. A. (2003). Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. *Proc Natl Acad Sci U S A* **100**, 15131–15136.
- Nishimura, Y., Shingai, M., Willey, R., Sadjadpour, R., Lee, W. R., Brown, C. R., Brenchley, J. M., Buckler-White, A., Petros, R. & other authors (2010). Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. *J Virol* **84**, 4769–4781.
- Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. (1998). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. *J Virol* **72**, 2855–2864.
- Shibata, R. & Adachi, A. (1992). SIV/HIV recombinants and their use in studying biological properties. *AIDS Res Hum Retroviruses* **8**, 403–409.
- Shimizu, Y., Okoba, M., Yamazaki, N., Goto, Y., Miura, T., Hayami, M., Hoshino, H. & Haga, T. (2006). Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene. *Microbes Infect* **8**, 105–113.
- Shinohara, K., Sakai, K., Ando, S., Ami, Y., Yoshino, N., Takahashi, E., Someya, K., Suzaki, Y., Nakasone, T. & other authors (1999). A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. *J Gen Virol* **80**, 1231–1240.
- Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J. & Sodroski, J. (1993). Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. *J Virol* **67**, 3978–3988.
- von Brunn, A., Brand, M., Reichhuber, C., Morys-Wortmann, C., Deinhardt, F. & Schödel, F. (1993). Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. *Vaccine* **11**, 817–824.
- Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M. & Kappes, J. C. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents Chemother* **46**, 1896–1905.
- Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A. & Sodroski, J. G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. *Nature* **393**, 705–711.
- Yamada, Y., Ochiai, C., Yoshimura, K., Tanaka, T., Ohashi, N., Narumi, T., Nomura, W., Harada, S., Matsushita, S. & Tamamura, H. (2010). CD4 mimics targeting the mechanism of HIV entry. *Bioorg Med Chem Lett* **20**, 354–358.
- Yoshimura, K., Harada, S., Shibata, J., Hatada, M., Yamada, Y., Ochiai, C., Tamamura, H. & Matsushita, S. (2010). Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. *J Virol* **84**, 7558–7568.
- Yusa, K., Maeda, Y., Fujioka, A., Monde, K. & Harada, S. (2005). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. *J Biol Chem* **280**, 30083–30090.
- Zhao, Q., Ma, L., Jiang, S., Lu, H., Liu, S., He, Y., Strick, N., Neamati, N. & Debnath, A. K. (2005). Identification of *N*-phenyl-*N'*-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. *Virology* **339**, 213–225.



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc



A CD4 mimic as an HIV entry inhibitor: Pharmacokinetics



Chie Hashimoto^a, Tetsuo Narumi^a, Hiroyuki Otsuki^b, Yuki Hirota^a, Hiroshi Arai^a, Kazuhisa Yoshimura^{c,d}, Shigeyoshi Harada^{c,d}, Nami Ohashi^a, Wataru Nomura^a, Tomoyuki Miura^b, Tatsuhiko Igarashi^b, Shuzo Matsushita^d, Hirokazu Tamamura^{a,*}

^aInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan

^bInstitute for Virus Research, Kyoto University, Kyoto 606-8507, Japan

^cAIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo 162-8640, Japan

^dCenter for AIDS Research, Kumamoto University, Kumamoto 860-0811, Japan

ARTICLE INFO

Article history:

Received 17 September 2013

Revised 5 October 2013

Accepted 5 October 2013

Available online 17 October 2013

Keywords:

CD4 mimic

HIV entry inhibitor

Intravenous administration

Pharmacokinetics

ABSTRACT

To date, several small molecules of CD4 mimics, which can suppress competitively the interaction between an HIV-1 envelope glycoprotein gp120 and a cellular surface protein CD4, have been reported as viral entry inhibitors. A lead compound **2** (YYA-021) with relatively high potency and low cytotoxicity has been identified previously by SAR studies. In the present study, the pharmacokinetics of the intravenous administration of compound **2** in rats and rhesus macaques is reported. The half-lives of compound **2** in blood in rats and rhesus macaques suggest that compound **2** shows wide tissue distribution and relatively high distribution volumes. A few hours after the injection, both plasma concentrations of compound **2** maintained micromolar levels, indicating it might have promise for intravenous administration when used combinatorially with anti-gp120 monoclonal antibodies.

© 2013 Elsevier Ltd. All rights reserved.

1. Introduction

Several anti-HIV-1 drugs, including protease inhibitors and integrase inhibitors have been developed and have contributed to the highly active anti-retroviral therapy (HAART) used to treat AIDS.¹ Prevention of the HIV-1 infection of its target cells² is however a legitimate goal and the viral attachment process is an important target for the development of the drugs which could forestall such infection. The dynamic and supramolecular entry of human immunodeficiency virus type 1 (HIV-1) into target cells is initiated by the interaction of a viral envelope glycoprotein gp120 with the cell surface protein CD4.³ Sequential binding of CD4 and a co-receptor (CCR5 or CXCR4) to gp120 can trigger a series of conformational rearrangements of gp41, a viral transmembrane glycoprotein mediating fusion between the viral and cellular membranes.^{3–5} Control, especially of dynamic conformational changes of the envelope glycoproteins is a very attractive option.⁷ To date, several small molecules that mimic CD4 have been developed as HIV-1 entry inhibitors, which competitively block the binding of gp120 to CD4⁸ and the potential of these CD4 mimics has been explored (Fig. 1).^{9–11} Furthermore, the interaction of CD4 mimics with a highly conserved pocket on gp120, designated as the 'Phe43 cavity', induces conformational




Figure 1. Structures of NBD-556 (**1**) and YYA-021 (**2**).

changes in gp120,¹² a process which occurs with unfavorable binding entropy, and leads to a favorable enthalpy change similar to that caused by binding of the soluble CD4 binding to gp120. Thus, these unique properties render CD4 mimics valuable not only as entry inhibitors but also as 'envelope protein openers' and putatively, stimulants when combined with neutralizing antibodies.¹³

Through our SAR studies a lead compound YYA-021 (**2**) with relatively high potency and low cytotoxicity has been found,¹¹ although the original compound NBD-556 (**1**) had relatively high cytotoxicity. Pharmacokinetic (PK) studies were performed to assess the potential of compound **2** for clinical application and in addition, the possibility and the effectiveness of its use in combination with neutralization antibodies are discussed.

* Corresponding author. Tel.: +81 3 5280 8036; fax: +81 3 5280 8039.

E-mail address: tamamura.mr@tmd.ac.jp (H. Tamamura).




Figure 2. A calibration curve of compound 2-HCl for calculating PK in rats.

2. Results and discussion

2.1. Calibration curve

Compound **2** was converted to its hydrochloride salt **2-HCl**, by treatment with 4 M HCl in dioxane. Standard solutions in saline of this HCl salt at concentrations over a range of 0–250 µg/mL were prepared and a calibration curve was constructed using the ratio of observed HPLC peak areas and concentrations of **2-HCl** to demonstrate the linearity shown in Figure 2.¹⁴ The corresponding linear regression equation is $Y = 0.1345X$ ($R^2 = 0.9981$). Plasma concentrations of **2-HCl** were measured using this equation. The calibration curve shown in SD Figure S5C for the concentrations of compound **2** in plasma of a rhesus macaque was constructed using standard solutions of **2-HCl** in saline at concentrations over a range of 0–312.5 µg/mL. The linear regression equation in this case is $Y = 0.034X$ ($R^2 = 0.9927$). For adsorption of compound **2** by blood cells of a rhesus macaque, a calibration curve was constructed using standard solutions of **2-HCl** in saline at concentrations over a range of 0–950 µg/mL. The linear regression equation is $Y = 0.0553X$ ($R^2 = 0.9263$) and the curve is shown in SD Figure S7C.

2.2. Pharmacokinetics in rats

The primary stock solution of **2-HCl** was prepared in saline (2.5 mg/mL). Initially, the acute toxicity of compound **2** in rats was investigated to determine its maximum tolerated dose. The HCl salt, compound **2-HCl**, (0, 0.5, 1.0, 2.5 and 5.0 mg) was administered by tail vein injection into Jcl:SD rats (3 or 4 rats for each dose). Rats with the 5.0 mg administration showed a relatively low increase in the body weight although the intake amount of bait and water increased remarkably two weeks after administration, compared to the other rats (Supplementary data, SD Figs. S1 and S2). This observation suggested abnormalities such as renal and hepatic dysfunction and as a result, the maximum dose in rats of **2-HCl** was determined to be 2.5 mg.

Compound **2-HCl** (2.5 mg) in saline (1 mL) was administered at a level of 14 mg/kg by tail vein injection into Jcl:SD rats. Blood was collected from the tail vein into centrifugal blood collection tubes 15, 30, 45, 60, 120 and 240 min after administration of **2-HCl**. Plasma (50 µL) obtained from the blood sample was mixed with phenol in saline (final volume 60 µL) and centrifuged at 2000g for 3 min to remove any protein. The resultant supernatant was used in the analysis. A 50 µL aliquot of each filtrate was injected into HPLC by an autosampler. Compound **2** was detected in the HPLC analysis and was characterized by ESI-TOF-MS. The HPLC chart of the filtrate collected 30 min after administration of compound **2** is shown in Figure 3. Concentrations in blood of compound **2** after administration (15, 30, 45, 60, 120 and 240 min) were calculated using the calibration curve (SD Fig. S4) and plotted as shown in Figure 4.¹⁵

Using the data measured at 15, 30, 45, 60, 120 and 240 min, the half-life was calculated as 8.4 min by curve fitting with a one-compartment model based on GraphPad Prism Version 5.04 (GraphPad Software, CA, U.S.A). The initial concentration was calculated as 17.3 µg/mL. Compound **2** has a low molecular weight (317.4) and some level of hydrophobicity based on its structure, suggesting that the renal excretion is unlikely. At a dose of 2500 (µg)/initial concentration 17.3 (µg/mL), the volume of distribution was calculated as 145 mL, suggesting widespread tissue distribution of **2** as a result of its hydrophobicity.




Figure 3. HPLC chart of rat plasma 30 min after intravenous administration of compound **2**. The plasma sample was eluted with a linear gradient of 20–35% CH₃CN (0.1% TFA, in 30 min). Peak 8 (retention time: 12.13 min) corresponds to the internal standard (phenol) and peak 9 (retention time: 17.67 min) corresponds to compound **2**.




Figure 4. Plots of concentrations in rat blood of compound **2** after administration (15, 30, 45, 60, 120 and 240 min). Half-life is calculated as 0.141 h (8.4 min). The plasma of a representative rat was used for the analyses.




Figure 6. Plots of macaque blood concentrations of compound **2** after administration of **2-HCl** (0.5, 1, 2, 4 and 24 h). Half-life is calculated as 1.64 h (98.4 min). The plasma of a rhesus macaque was used for the analyses.

2.3. Pharmacokinetics in a rhesus macaque

The primary stock solution of the **2-HCl** was prepared in potassium-free phosphate-buffered saline ($\text{Na}_2\text{HPO}_4 + \text{NaH}_2\text{PO}_4 + \text{NaCl}$, pH 7.4) (2.4 mg/mL) to avoid hyperkalemia and acidosis. Initially, the acute toxicity observed by treatment with **2-HCl** in a rhesus macaque was investigated to determine the maximum tolerated dose. **2-HCl** (14.1, 35.3 and 70.6 mg) was administered by cephalic vein injection into a rhesus macaque (one macaque for each dose). A macaque administered 70.6 mg, showed abnormalities such as mydriasis, prolonged PR interval in the electrocardiogram and bradycardia, while acute toxicity was not observed following the administration of **2-HCl** at levels up to 35.3 mg¹⁶ and the maximum tolerated dose in a rhesus macaque was determined to be 35.3 mg (6.7 mg/kg). The macaque which had been administered 70.6 mg of **2-HCl** was treated by an emergency intervention with dobutamine (iv).

Compound **2-HCl** (70.6 mg) was intravenously administered at 13.4 mg/kg into a rhesus macaque. Blood (3.0 mL) was collected from cephalic vein 0, 0.5, 1, 2, 4 and 24 h after administration of the hydrochloride using winged needles. Plasma (60 µL) obtained from the blood sample was mixed with MeOH (200 µL) to remove plasma proteins and then centrifuged at 2000g for 3 min at room temperature in a microcentrifuge (MCF-2360, LMS Co., Ltd., Tokyo, Japan). A 228 µL aliquot of each supernatant was mixed with 12 µL of phenol in saline (stock solution: 0.3 mg/mL) to give a final

concentration of phenol of 150 µg/mL, then filtered. A 200 µL aliquot of each filtrate was analyzed by HPLC using phenol as an internal standard. Compound **2** was detected in the HPLC analysis of each filtrate and its peak was characterized by ESI-TOF-MS. The HPLC of the filtrate prepared 30 min after administration of **2-HCl** is shown in Figure 5. Blood concentrations of compound **2** after 0.5, 1, 2, 4 or 24 h administration were calculated using the calibration curve (SD Fig. S6) and plotted as shown in Figure 6.

Using the time-course data, the half-life was calculated as 98.4 min by curve fitting based on GraphPad Prism Version 5.04 (GraphPad Software, CA, U.S.A.). The initial concentration in blood was also calculated as 1.50 µg/mL. In a macaque, this suggests that the renal excretion is not possible and this was by the absence of compound **2** in the HPLC analysis of the urine (SD). The distribution volume was calculated as 47.1 L; the dose 70.6 (mg)/initial concentration 1.50 (µg/mL) ratio suggests tissue distribution.

2.4. Adsorption of compound 2 to blood cells of a rhesus macaque

The question of whether compound **2** can be attached to and adsorbed into blood cells was investigated. Initially, **2-HCl** was added to blood (1 mL) of a rhesus macaque reaching a final concentration of 1 mg/mL. This mixture was incubated at 37 °C for 0, 1 and 2 h, and then centrifuged at 3600 rpm for 5 min at room temperature in a microcentrifuge to separate plasma (730 µL) from




Figure 5. HPLC chart of macaque plasma 30 min after intravenous administration of **2-HCl**. The plasma sample was eluted with a linear gradient of 20–35% CH_3CN (0.1% TFA, in 30 min). Peak 10 (retention time: 12.44 min) corresponds to the internal standard (phenol) and peak 13 (retention time: 17.98 min) corresponds to compound **2**.

blood cells. In addition, plasma (0.5 mL) was added to the blood cells incubated for 1 h, then the mixture was incubated again for 1 h to separate plasma (730 μ L) from the blood cells. Blood cell samples were prepared by mixing the blood cells with 480 μ L of PBS and diluting the mixture to 1 mL with PBS. Blood cell samples were sonicated to disrupt cell membranes then both plasma and blood cell samples (60 μ L each) were vortex-mixed with 200 μ L of MeOH, then centrifuged at 2000g for 3 min at room temperature. A 228 μ L aliquot of each supernatant was mixed with 12 μ L of phenol in saline (final concentration: 600 μ g/mL) and filtered. A 200 μ L aliquot of each filtrate was injected to HPLC by an auto-sampler (SD Fig. S8).

The fractions of plasma and blood cells were analyzed by HPLC to quantify compound **2** (Fig. 7). The results showed that incubation enhanced the attachment or adsorption of compound **2** to blood cells; incubation for 1 or 2 h led to percentages of 39.7% and 39.3%, respectively, in distribution in cells, prior to incubation there was a distribution percentage of 34.8% in cells. Furthermore, compound **2**, which was adsorbed into blood cells, was significantly redistributed in plasma when fresh plasma was added; the addition of plasma to blood cells incubated for 1 h and a further incubation for 1 h caused redistribution of compound **2** to plasma and a reduction of distribution percentages to cells from 39.7% to 11.5%. This suggests that compound **2**, which was attached to blood cells, might be transferred from the cells to plasma and subsequently distributed to tissues.

These results indicate that the concentration in blood of compound **2** might be reduced, ultimately to \sim 1 mg/mL (3 μ M) with 2–4 h treatments in rats (14 mg/kg) and rhesus macaques (13.4 mg/kg). The EC₅₀ value of compound **2** has been determined as 10–50 μ M in laboratory and primary HIV-1 strains.¹¹ Thus, in several hours after intravenous administration of compound **2** the efficacy might be diminished because the concentration in blood of compound **2** is being maintained below EC₅₀ levels. However, the amount administered cannot be increased because of the acute toxicity which is described in the previous section, although the concentration in blood of compound **2** does not reach its CC₅₀ level of 210 μ M.¹¹ Recently, we reported that CD4 mimics such as compound **1** enhance the binding potency of anti-gp120 monoclonal antibodies such as KD-247¹⁶ toward an envelope protein gp120, showing synergistic neutralization.¹³ Compound **2** also enhances the neutralizing activity of KD-247 against simian-human immunodeficiency virus (SHIV)-KS661 strain via highly synergistic interactions. When compound **2** is used in combination with anti-gp120 monoclonal antibodies such as KD-247, the level

of compound **2** of 3 μ M might be sufficient for neutralization in vivo and thus it might be possible to reduce the dose of compound **2**. In addition, we also found that compound **1** and CXCR4 antagonists such as T140² showed synergistic anti-HIV-1 activity.¹¹ Thus, a combinatorial use with co-receptor antagonists would be also effective for reduction of the dose of compound **2**.

3. Conclusion

CD4 mimics are attractive not only as HIV entry inhibitors but also possibly as cooperating agents for neutralizing antibodies. Binding of CD4 mimicking compounds to gp120 causes a conformational change in gp120. In this way, CD4 mimics function as 'envelope openers' and enhance the binding ability of anti-gp120 neutralizing antibodies. We discovered lead compound **2** with relatively high potency and low cytotoxicity in our previous study. In the current study, the pharmacokinetics of compound **2** in rats and rhesus macaques in the intravenous administration were investigated. Plots of plasma concentrations of compound **2** fitted with a one-compartment model provided calculation of half-lives of compound **2** in blood in rats and rhesus macaques: 8.4 and 98.4 min, respectively, suggesting that compound **2** is broadly distributed in tissues. A few hours post-injection, plasma concentrations of compound **2** in both species stabilized at micromolar levels. Consequently, compound **2** might have promise as a lead compound for the intravenous administration in a cocktail therapy with anti-gp120 monoclonal antibodies such as KD-247 and with co-receptor antagonists such as T140.²

4. Experimental

4.1. General information

A Cosmosil 5C18-ARII column (4.6 \times 250 mm, Nacalai Tesque, Inc., Kyoto, Japan) was used for analytical HPLC, with a linear gradient of CH₃CN containing 0.1% (v/v) TFA at a flow rate of 1 cm³ min⁻¹ on a JASCO PU-2089 plus (JASCO Corporation, Ltd., Tokyo, Japan), and eluents were detected by UV at 220 nm on a JASCO UV-2075 plus (JASCO Corporation, Ltd, Tokyo, Japan). Samples were injected by an autosampler on a JASCO AS-2075 plus (JASCO Corporation, Ltd, Tokyo, Japan). ESI-TOF-MS were recorded on a micrOTOF-2focus (Bruker Daltonics) mass spectrometer.

4.2. Calibration curve

To compound **2** (1.0 g) in MeOH (5 mL) was added 4 M HCl/dioxane (10 mL) and the mixture was stirred for 30 min at room temperature. The mixture was concentrated under reduced pressure and the **2**-HCl was precipitated in cooled Et₂O (yield: 1.2 g, quantitative).

To construct a pharmacokinetics calibration curve in a rat, standard stock solutions in saline of **2**-HCl; 263, 131.5, 65.8, 32.9 and 16.4 μ g/mL and an internal standard stock solution; 1.25 mg/mL phenol in saline were prepared. Each standard stock solution (22.8 μ L) was mixed with 1.2 μ L of the internal stock solution to give a total volume of 24 μ L, then filtered. A 20 μ L aliquot of each filtrate was injected to HPLC. The final concentration of **2**-HCl was 250, 125, 62.5, 31.3 or 15.6 μ g/mL and each sample contains 62.5 μ g/mL phenol. Elution was carried out with a linear gradient of 20–35% CH₃CN (0.1% TFA) over 30 min (SD Fig. S3). A calibration curve was constructed using the ratio of HPLC peak areas and concentrations of **2**-HCl to demonstrate the linearity as shown in Figure 2. The linear regression equation is $Y = 0.1345X$ ($R^2 = 0.9981$).

To construct a pharmacokinetics calibration curve in a rhesus macaque, standard stock solutions in saline of **2**-HCl (329, 164.5,




Figure 7. Quantitative analysis of compound **2** contained in macaque blood cells and plasma after incubation for 0, 1, or 2 h. 1 h + plasma means the addition of plasma (0.5 mL) to 1 h incubated blood cells followed by further incubation for 1 h. Concentrations of compound **2** in plasma are shown in black bars, and those in blood cells are shown in white bars.

82.3, 41.1, 20.6 and 10.3 $\mu\text{g/mL}$) and an internal standard stock solution of phenol in saline (3 mg/mL) were prepared. Each standard stock solution (22.8 μL) was mixed with 1.2 μL of the internal standard stock solution and filtered. A 20 μL aliquot of each filtrate was injected to HPLC. The final concentration of **2-HCl** was 312.5, 156.3, 78.1, 39.1, 19.5 and 9.77 $\mu\text{g/mL}$, each contained 150 $\mu\text{g/mL}$ phenol. Elution was carried out with a linear gradient of 20–35% CH_3CN (0.1% TFA) over 30 min. A calibration curve was constructed using the ratio of HPLC peak areas and concentrations of **2-HCl** to demonstrate the linearity as shown in SD Figure S5. The linear regression equation is $Y = 0.034X$ ($R^2 = 0.9927$).

To construct a calibration curve for the adsorption experiments, standard stock solutions in saline of **2-HCl**; 1000, 500, 250, 100, 50 $\mu\text{g/mL}$ and an internal standard stock solution of 12 mg/mL phenol in saline were prepared. Each standard stock solution (228 μL) was mixed with 12 μL of the internal stock solution and filtered. A 200 μL aliquot of each filtrate was injected to HPLC by an autosampler. The final concentration of **2-HCl** was 950, 475, 238, 95.0 and 47.5 $\mu\text{g/mL}$ and contained 600 $\mu\text{g/mL}$ phenol. Elution was carried out with a linear gradient of 20–35% CH_3CN (0.1% TFA) over 30 min. A calibration curve was constructed using the ratio of HPLC peak areas and concentrations of **2-HCl** to demonstrate the linearity shown in SD Figure S7. The linear regression equation is $Y = 0.0553X$ ($R^2 = 0.9263$).

4.3. Pharmacokinetics in rats

Experiments using rats were conducted in an animal facility under specific pathogen-free conditions, in compliance with institutional regulations approved by the Committee of Tokyo Medical and Dental University (Tokyo, Japan). Five-week-old Jcl:SD rats purchased from CLEA Japan, Inc. (Tokyo, Japan) were maintained for one week before experiments. Compound **2-HCl** (2.5 mg) in 1.0 mL of saline was administered by tail vein injection into 6 week-old Jcl:SD rats. Blood was collected from the tail vein into centrifugal blood collection tubes (E-DS11, Eiken Chemical Co., Ltd., Tokyo, Japan) 15, 30, 45, 60, 120 and 240 min after administration. Blood was centrifuged at 2000g for 3 min at room temperature to separate plasma and stored at -80°C before use. A freeze-thawed plasma sample (50 μL) was mixed with 10 μL of phenol in saline (stock solution: 0.375 mg/mL, giving a final concentration of 62.5 $\mu\text{g/mL}$) and filtered at 2000g for 3 min in a microcentrifuge (MCF-2360, LMS Co., Ltd., Tokyo, Japan). A 50 μL aliquot of each filtrate was injected into an HPLC. Elution was carried out with a linear gradient of 20–35% CH_3CN (0.1% TFA) over 30 min shown in SD Figure S4. Compound **2** was detected in the HPLC analysis and its peak was characterized by ESI-TOF-MS (m/z calcd for $\text{C}_{18}\text{H}_{28}\text{N}_3\text{O}_2$ $[\text{M}+\text{H}]^+$ 318.22, found 318.19).

4.4. Pharmacokinetics in a rhesus macaque

Experiments using an adult female rhesus macaque, seven years old, were conducted in a biosafety level 3 animal facility, in compliance with institutional regulations approved by the Committee for Experimental Use of Nonhuman Primates of the Institute for Virus Research, Kyoto University (Kyoto, Japan). Compound **2-HCl** (70.6 mg) in 30 mL of 0.1 M sodium phosphate buffer containing NaCl (pH 7.4) was administered by cephalic vein injection. Blood (3.0 mL) was collected from the cephalic vein 0, 0.5, 1, 2, 4 and 24 h after administration using winged needles. Blood was centrifuged at 3600 rpm for 5 min at room temperature to separate plasma then stored at -80°C before use. A freeze-thawed plasma sample (60 μL) was vortex-mixed with MeOH (200 μL) and centrifuged at 2000g for 3 min at room temperature. A 228 μL aliquot of each supernatant was mixed with 12 μL of phenol in saline (stock solution: 0.3 mg/mL, final concentration: 150 $\mu\text{g/mL}$) and filtered.

A 200 μL aliquot of each filtrate was injected into HPLC by an autosampler. Elution was carried out with a linear gradient of 20–35% CH_3CN (0.1% TFA) over 30 min shown in SD Figure S6. Compound **2** was detected in the HPLC analysis of each filtrate and its peak was characterized by ESI-TOF-MS (m/z calcd for $\text{C}_{18}\text{H}_{28}\text{N}_3\text{O}_2$ $[\text{M}+\text{H}]^+$ 318.22, found 318.19).

4.5. Adsorption experiments of compound 2 to blood cells of a rhesus macaque

Compound **2-HCl** in saline (5 mg/mL, 0.25 mL) was added to blood (1.0 mL) collected from a macaque, and incubated at 37°C for 0, 1 and 2 h. After incubation, plasma samples (730 μL) were separated by centrifugation at 3600 rpm for 5 min at room temperature, and PBS (480 μL) was added to the resulting precipitates, increasing their total volume to 1.0 mL, and producing blood cell samples. In addition, plasma (0.5 mL) was added to the blood cells after 1 h incubation and the mixture was incubated again for 1 h to separate plasma (730 μL) and blood cells. The separated plasma and blood cell samples were stored at -80°C before use. Freeze-thawed plasma samples (60 μL) were vortex-mixed with MeOH (200 μL) and centrifuged at 2000g for 3 min at room temperature. Freeze-thawed blood cell samples (200 μL) were sonicated to disrupt cell membranes (Sonifier 250, Branson Ultrasonics, Emerson Japan Ltd., Kanagawa, Japan), and 60 μL of the sonicated products was vortex-mixed with MeOH (200 μL) and centrifuged at 2000g for 3 min at room temperature. A 228 μL aliquot of each supernatant obtained from both plasma and blood cell samples was mixed with 12 μL of phenol in saline (stock solution: 12 mg/mL, final concentration: 600 $\mu\text{g/mL}$) and filtered. After filtration, a 200 μL aliquot of each filtrate was injected into HPLC by an autosampler. Elution was carried out with a linear gradient of 20–35% CH_3CN (0.1% TFA) over 30 min and is shown in SD Figure S8.

Acknowledgments

This work was supported in part by Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, and Health and Labour Sciences Research Grants from Japanese Ministry of Health, Labor, and Welfare. The authors thank Ms. Misako Namae and Professor Hiroshi Nishina, Medical Research Institute, Tokyo Medical and Dental University, for providing us with methods for the collection of blood from rats. The authors also thank Dr. Fumiyo Yamashita, Graduate School of Pharmaceutical Sciences, Kyoto University, for assistance with the calculation of the pharmacokinetics. Our thanks are also extended to Ms. Yuko Yamada and Ms. Aki Ohya, from our laboratory, for teaching us techniques for analysis of plasma samples.

Supplementary data

Supplementary data (figures of changes on body weight and on intake amounts of bait and water in rats, tables of HPLC peak areas and HPLC charts) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2013.10.005>.

References and notes

- Hashimoto, C.; Tanaka, T.; Narumi, T.; Nomura, W.; Tamamura, H. *Expert Opin. Drug Discovery* 2011, 6, 1067.
- (a) Tamamura, H.; Xu, Y.; Hattori, T.; Zhang, X.; Arakaki, R.; Kanbara, K.; Omagari, A.; Otaka, A.; Ibuka, T.; Yamamoto, N.; Nakashima, H.; Fujii, N. *Biochem. Biophys. Res. Commun.* 1998, 253, 877; (b) Tamamura, H.; Omagari, A.; Oishi, S.; Kanamoto, T.; Yamamoto, N.; Peiper, S. C.; Nakashima, H.; Otaka, A.; Fujii, N. *Bioorg. Med. Chem. Lett.* 2000, 10, 2633; (c) Fujii, N.; Oishi, S.; Hiramatsu, K.; Araki, T.; Ueda, S.; Tamamura, H.; Otaka, A.; Kusano, S.; Terakubo, S.; Nakashima, H.; Broach, J. A.; Trent, J. O.; Wang, Z.; Peiper, S. C. *Angew. Chem., Int. Ed.* 2003, 42, 3251; (d) Tamamura, H.; Hiramatsu, K.; Ueda,

- S.; Wang, Z.; Kusano, S.; Terakubo, S.; Trent, J. O.; Peiper, S. C.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. *J. Med. Chem.* **2005**, *48*, 380; (e) Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.; Oishi, S.; Esaka, A.; Trent, J. O.; Nakashima, H.; Yamamoto, N.; Peiper, S. C.; Otaka, A.; Fujii, N. *J. Med. Chem.* **2005**, *48*, 3280.
3. Chan, D. C.; Kim, P. S. *Cell* **1998**, *93*, 681.
 4. Eckert, D. M.; Kim, P. S. *Annu. Rev. Biochem.* **2001**, *70*, 777.
 5. Wyatt, R.; Sodroski, J. *Science* **1984**, *1998*, 280.
 6. Berger, E. A.; Murphy, P. M.; Farber, J. M. *Annu. Rev. Immunol.* **1999**, *17*, 657.
 7. (a) Wild, C. T.; Shugars, D. C.; Greenwell, T. K.; McDanal, C. B.; Matthews, T. J.; Chan, D. C.; Fass, D. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, 9770; (b) Berger, J. M.; Kim, P. S. *Cell* **1997**, *89*, 263; (c) Otaka, A.; Nakamura, M.; Nameki, D.; Kodama, E.; Uchiyama, S.; Nakamura, S.; Nakano, H.; Tamamura, H.; Kobayashi, Y.; Matsuoka, M.; Fujii, N. *Angew. Chem., Int. Ed.* **2002**, *41*, 2937; (d) Nomura, W.; Hashimoto, C.; Ohya, A.; Miyauchi, K.; Urano, E.; Tanaka, T.; Narumi, T.; Nakahara, T.; Komano, J. A.; Yamamoto, N.; Tamamura, H. *ChemMedChem* **2012**, *7*, 205; (e) Hashimoto, C.; Nomura, W.; Ohya, A.; Urano, E.; Miyauchi, K.; Narumi, T.; Aikawa, H.; Komano, J. A.; Yamamoto, N.; Tamamura, H. *Bioorg. Med. Chem.* **2012**, *20*, 3287; (f) Nomura, W.; Hashimoto, C.; Suzuki, T.; Ohashi, N.; Fujino, M.; Murakami, T.; Yamamoto, N.; Tamamura, H. *Bioorg. Med. Chem.* **2013**, *21*, 4452.
 8. Zhao, Q.; Ma, L.; Jiang, S.; Lu, H.; Liu, S.; He, Y.; Strick, N.; Neamati, N.; Debnath, A. K. *Virology* **2005**, *339*, 213.
 9. (a) Madani, N.; Schön, A.; Princiotta, A. M.; LaLonde, J. M.; Courter, J. R.; Soeta, T.; Ng, D.; Wang, L.; Brower, E. T.; Xiang, S.-H.; Do Kwon, Y.; Huang, C.-C.; Wyatt, R.; Kwong, P. D.; Freire, E.; Smith, A. B., 3rd; Sodroski, J. *Structure* **2008**, *16*, 1689; (b) LaLonde, J. M.; Elban, M. A.; Courter, J. R.; Sugawara, A.; Soeta, T.; Madani, N.; Princiotta, A. M.; Kwon, Y. D.; Kwong, P. D.; Schön, A.; Freire, E.; Sodroski, J.; Smith, A. B., 3rd *Bioorg. Med. Chem. Lett.* **2011**, *20*, 354; (c) LaLonde, J. M.; Kwon, Y. D.; Jones, D. M.; Sun, A. W.; Courter, J. R.; Soeta, T.; Kobayashi, T.; Princiotta, A. M.; Wu, X.; Schön, A.; Freire, E.; Kwong, P. D.; Mascola, J. R.; Sodroski, J.; Madani, N.; Smith, A. B., 3rd *J. Med. Chem.* **2012**, *55*, 4382.
 10. Curreli, F.; Choudhury, S.; Pyatkin, I.; Zagorodnikov, V. P.; Bulay, A. K.; Altieri, A.; Kwon, Y. D.; Kwon, P. D.; Debnath, A. K. *J. Med. Chem.* **2012**, *55*, 4764.
 11. (a) Yamada, Y.; Ochiai, C.; Yoshimura, K.; Tanaka, T.; Ohashi, N.; Narumi, T.; Nomura, W.; Harada, S.; Matsushita, S.; Tamamura, H. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 354; (b) Narumi, T.; Ochiai, C.; Yoshimura, K.; Harada, S.; Tanaka, T.; Nomura, W.; Arai, H.; Ozaki, T.; Ohashi, N.; Matsushita, S.; Tamamura, H. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 5853; (c) Narumi, T.; Arai, H.; Yoshimura, K.; Harada, S.; Nomura, W.; Matsushita, S.; Tamamura, H. *Bioorg. Med. Chem.* **2011**, *19*, 6735; (d) Narumi, T.; Arai, H.; Yoshimura, K.; Harada, S.; Hitota, Y.; Ohashi, N.; Hashimoto, C.; Nomura, W.; Matsushita, S.; Tamamura, H. *Bioorg. Med. Chem.* **2013**, *21*, 2518.
 12. Schön, A.; Madani, N.; Klein, J. C.; Hubicki, A.; Ng, D.; Yang, X.; Smith, A. B., 3rd; Sodroski, J.; Freire, E. *Biochemistry* **2006**, *45*, 10973; (b) Schön, A.; Lam, S. Y.; Freire, E. *Future Med. Chem.* **2011**, *3*, 1129.
 13. Yoshimura, K.; Harada, S.; Shibata, J.; Hatada, M.; Yamada, Y.; Ochiai, C.; Tamamura, H.; Matsushita, S. *J. Virol.* **2010**, *84*, 7558.
 14. Mao, S.; Jin, H.; Bi, Y.-Q.; Liang, Z.; Li, H.; Hou, S.-X. *Chem. Pharm. Bull.* **2007**, *55*, 753.
 15. Sakai-Kato, K.; Nanjo, K.; Kawanishi, T.; Okuda, H. *Chem. Pharm. Bull.* **2012**, *60*, 391.
 16. Eda, Y.; Takizawa, M.; Murakami, T.; Maeda, H.; Kimachi, K.; Yonemura, H.; Koyanagi, S.; Shiosaki, K.; Higuchi, H.; Makizumi, K.; Nakashima, T.; Osatomi, K.; Tokiyoshi, S.; Matsushita, S.; Yamamoto, N.; Honda, M. *J. Virol.* **2006**, *80*, 5552.



Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail

Takeo Kuwata¹, Kaori Takaki¹, Ikumi Enomoto¹, Kazuhisa Yoshimura² and Shuzo Matsushita^{1*}

¹ Center for AIDS Research, Kumamoto University, Kumamoto, Japan

² AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan

Edited by:

Akio Adachi, The University of Tokushima Graduate School, Japan

Reviewed by:

Tetsuro Matano, University of Tokyo, Japan

Tsutomu Murakami, National Institute of Infectious Diseases, Japan
Hirofumi Akari, Kyoto University, Japan

*Correspondence:

Shuzo Matsushita, Center for AIDS Research, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto 860-0811, Japan.
e-mail: shuzo@kumamoto-u.ac.jp

The role of antibodies in protecting the host from human immunodeficiency virus type 1 (HIV-1) infection is of considerable interest, particularly because the RV144 trial results suggest that antibodies contribute to protection. Although infection of non-human primates with simian immunodeficiency virus (SIV) is commonly used as an animal model of HIV-1 infection, the viral epitopes that elicit potent and broad neutralizing antibodies to SIV have not been identified. We isolated a monoclonal antibody (MAb) B404 that potently and broadly neutralizes various SIV strains. B404 targets a conformational epitope comprising the V3 and V4 loops of Env that intensely exposed when Env binds CD4. B404-resistant variants were obtained by passaging viruses in the presence of increasing concentration of B404 in PM1/CCR5 cells. Genetic analysis revealed that the Q733stop mutation, which truncates the cytoplasmic tail of gp41, was the first major substitution in Env during passage. The maximal inhibition by B404 and other MAbs were significantly decreased against a recombinant virus with a gp41 truncation compared with the parental SIVmac316. This indicates that the gp41 truncation was associated with resistance to antibody-mediated neutralization. The infectivities of the recombinant virus with the gp41 truncation were 7,900-, 1,000-, and 140-fold higher than those of SIVmac316 in PM1, PM1/CCR5, and TZM-bl cells, respectively. Immunoblotting analysis revealed that the gp41 truncation enhanced the incorporation of Env into virions. The effect of the gp41 truncation on infectivity was not obvious in the HSC-F macaque cell line, although the resistance of viruses harboring the gp41 truncation to neutralization was maintained. These results suggest that viruses with a truncated gp41 cytoplasmic tail were selected by increased infectivity in human cells and by acquiring resistance to neutralizing antibody.

Keywords: SIV, gp41, truncation, infectivity, resistance, neutralization, antibody

INTRODUCTION

The RV144 trial demonstrated 31% vaccine efficacy for preventing human immunodeficiency virus type 1 (HIV-1) infection (Rerks-Ngarm et al., 2009). Antibodies against the HIV-1, particularly against the V1/V2 loops, correlate inversely with infection risk (Haynes et al., 2012). Further recent isolation of monoclonal antibodies (MAbs) that neutralize a broad range of HIV-1 strains suggest the possibility for developing a vaccine that can induce cross-neutralizing antibodies effective for various HIV-1 strains (Kwong and Mascola, 2012). Although non-human primate models of simian immunodeficiency virus (SIV) infection can facilitate the evaluation of immunogens, epitopes and immune correlates, no potent and broad neutralizing MAb against SIV had been available.

To understand the mechanisms involved in neutralization of infectivity by antibodies in an SIV model, we recently isolated MAb B404 from a SIVsmH635FC-infected rhesus macaque, which potently and broadly neutralizes various SIV strains, such as SIVsmE543-3, SIVsmE660 and the neutralization-resistant variants, genetically diverse SIVmac316, and highly

neutralization-resistant SIVmac239 (Kuwata et al., 2011). The B404 epitope, which comprises the V3 and V4 loops of Env and is intensely exposed by ligation of Env to CD4, is the target for potent and broad neutralization of SIV (Kuwata et al., 2013). Vigorous induction of B404-like neutralizing antibodies using the specific VH3 gene with a long complementarity-determining region 3 loop and λ light chain was observed in four SIVsmH635FC-infected macaques. The B404-resistant variants were induced by passaging viruses in the presence of increasing concentrations of B404. Genetical analysis of the gp120 region of B404-resistant variants revealed that the mutations in the C2 region of Env were important for the resistance to antibody-mediated neutralization (Kuwata et al., 2013).

In the present study, we further analyzed B404-resistant variants and determined the precise region responsible for the resistance to antibody-mediated neutralization. Genetic analysis of viruses during passage in the presence of B404 as well as phenotypic analysis using recombinant viruses revealed that a truncation of the gp41 cytoplasmic tail was the primary step leading to escape from neutralization.

MATERIALS AND METHODS

CELLS

PM1 (Lusso et al., 1995), PM1/CCR5 (Yusa et al., 2005), and HSC-F (Akari et al., 1999) cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% fetal bovine serum (FBS). TZM-bl (Platt et al., 1998; Derdeyn et al., 2000; Wei et al., 2002; Takeuchi et al., 2008) and 293T (DuBridge et al., 1987) cells were maintained in Dulbecco's modified Eagle's medium containing 10% FBS.

GENETIC ANALYSIS OF B404-RESISTANT VARIANTS

The induction of variants resistant to Fab-B404 (Kuwata et al., 2011) from SIVmac316 (Mori et al., 1992) harboring full-length gp41 was performed as described previously (Yoshimura et al., 2006; Hatada et al., 2010; Kuwata et al., 2013). Briefly, 5,000 TCID₅₀ (50% tissue culture infectious dose) SIVmac316 was incubated with 5 ng/ml Fab-B404 for 30 min at 37°C. Then, 5 × 10⁴ PM1/CCR5 cells were added to the virus–Fab mixture. After incubation for 5 h, cells were washed with phosphate-buffered saline (PBS) and resuspended in RPMI 1640 supplemented with 10% FBS without Fab-B404. The culture supernatant was harvested 7 days later and used to infect fresh PM1/CCR5 cells for the next round of culture in the presence of increasing concentrations of Fab-B404. Proviral DNA samples were extracted from cells using a QIAamp DNA Blood Mini Kit (QIAGEN, Hilden, Germany) after 8, 17, 20, 23, and 26 passages as well as from P26C cells obtained after 26 passages in the absence of Fab-B404. The gp120 region was amplified using Platinum Taq DNA Polymerase High Fidelity (Invitrogen, Carlsbad, CA, USA) with primers SEnv-F (5'-ATG GGA TGT CTT GGG AAT CAG C-3') and SER1 (5'-CCA AGA ACC CTA GCA CAA AGA CCC-3'). The whole *env* gene was amplified with primers SRev-F (5'-GGT TTG GGA ATA TGC TAT GAG-3') and SEnv-R (5'-CCT ACT AAG TCA TCA TCT T-3'). The polymerase chain reaction (PCR) products were cloned using a TA cloning kit (Invitrogen), and subjected to sequencing. Nucleotide sequences were aligned and analyzed phylogenetically using Molecular Evolutionary Genetics Analysis version 5 (MEGA5) (Tamura et al., 2011).

CONSTRUCTION OF INFECTIOUS MOLECULAR CLONES WITH THE Env REGION FROM B404-RESISTANT VARIANTS

One of the clones from passage 26, P26B404 clone 26, was selected for construction of recombinant viruses, because this clone had mutations typical of the major population of P26B404 variants. Infectious molecular clones SS, SN, and NS were generated by replacing fragments *SphI*–*SacI* [nucleotides (nt) 6,446–9,226], *SphI*–*NheI* (nt 6,446–8,742), and *NheI*–*SacI* (nt 8,742–9,226) with the corresponding regions of SIVmac316, respectively. Mutants F277V and N295S, which have point mutations at amino acid residues 277 and 295 of Env, respectively, were constructed by PCR mutagenesis using the SIVmac316 plasmid as template. The changes from phenylalanine (TTC) to valine (GTC) in F277V and asparagine (AAT) to serine (AGT) in N295S were introduced using primers F277V_{Fw} (5'-TTG GTT TGG CGT CAA TGG TAC TAG GGC-3'), F277V_{Rv} (5'-GTA CCA TTG ACG CCA AAC CAA G-3'), N295S_{Fw} (5'-GGCAAT AGT AGT AGA ACCATA ATT AG-3'), and N295S_{Rv} (5'-AAT TAT GGT TCT ACT ACT ATT GCC-3').

Mutant and parental SIVmac316 plasmids were transfected into 293T cells using X-tremeGENE 9 DNA Transfection Reagent (Roche Molecular Biochemicals, Mannheim, Germany). After 2 days, the supernatants containing viruses were filtered (0.45 μm) and stored at –80°C.

ANALYSIS OF VIRAL INFECTIVITY

For determination of TCID₅₀ in PM1 and PM1/CCR5 cells, 5 × 10⁴ cells in 50 μl were inoculated with 50 μl serially diluted virus stocks in a 96-well plate and cultured for 2 weeks. Virus replication was judged by observation of cytopathic effects (CPE) by light microscopy. The TCID₅₀ in TZM-bl cells was determined by measuring luciferase activities. Briefly, 100 μl medium, 50 μl serially diluted virus stock, and 50 μl 1 × 10⁴ cells containing 37.5 μg/ml diethylaminoethyl (DEAE) dextran were added to the wells of a 96-well plate. The plate was then incubated at 37°C for 2 days. After washing with PBS, cells were lysed with 30 μl cell lysing buffer (Promega, Madison, WI, USA) for 15 min at room temperature (RT) and then 10 μl of cell lysate was transferred to a 96-well white solid plate (Costar, Cambridge, MA, USA). Luciferase activity was measured using a Centro XS3 LB960 microplate luminometer (Berthold Technologies, Bad Wildbad, Germany) and a luciferase assay system (Promega). The TCID₅₀ was calculated according to the formula of Reed and Muench (1938).

Infectivity of viruses in PM1, PM1/CCR5, and HSC-F cells was evaluated by detecting infected cells using flow cytometry as described previously (Kuwata et al., 2011). Briefly, PM1 and PM1/CCR5 cells were adjusted to 1 × 10⁶ cells/ml and HSC-F cells were adjusted to 5 × 10⁶ cells/ml. Aliquots of 100 μl cells per well in a 24-well plate were inoculated with 100 μl of diluted virus stocks. After incubation for 6 h, 800 μl fresh medium was added to wells. One-half of the cells in each well were collected at 4, 7, and 10 days post-inoculation. Cells were washed with PBS and fixed with IC Fixation Buffer (eBioscience, San Diego, CA, USA). After washing with Permeabilization Buffer (eBioscience) twice, the cells were intracellularly stained with 4 μg/ml (50 μl) anti-p27 Fab, B450 (Kuwata et al., 2011) by incubation for 20 min at RT. The cells were then incubated with 50 μl anti-HA antibody (1:200; 3F10, Roche Molecular Biochemicals) for 20 min at RT followed by incubation with 50 μl of anti-rat-FITC (1:500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 20 min at RT. The stained cells were analyzed using a FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). Frequencies of infected cells were determined by comparison with an uninfected control. Data analysis was performed using FlowJo (TreeStar, San Carlos, CA, USA).

All infectivity experiments were performed at least twice and the representative results are shown.

ANALYSIS OF NEUTRALIZING ACTIVITIES

The Fab clones B404 and K8, isolated from an SIV-infected macaque (Kuwata et al., 2011), and murine MAb M318T (Matsumi et al., 1995) were used to examine the sensitivity of viruses to antibody-mediated neutralization in TZM-bl cells as described previously (Kuwata et al., 2011). Briefly, 100 μl serially diluted antibodies in duplicate were incubated with 200 TCID₅₀ (50 μl) of virus in a 96-well plate. After incubation for 1 h at 37°C, 100 μl

of 1×10^5 TZM-bl cells/ml containing 37.5 $\mu\text{g/ml}$ DEAE dextran were added. After incubation for 2 days, luciferase activities were measured as described above for the analysis of viral infectivity. The 50% inhibitory concentrations (IC_{50}) and maximal percent of inhibition (MPI) were calculated from the average values by non-linear regression using Prism5 (GraphPad Software, San Diego, CA, USA).

Sensitivity to neutralization by B404 in macaque cells was analyzed using HSC-F cells, a cynomolgus macaque cell line immortalized by infection with *Herpesvirus saimiri* (Akari et al., 1999). Fab-B404 was serially diluted and 50 μl aliquots were mixed with 50 μl undiluted or 10-fold diluted virus in a 96-well plate. After 1 h incubation at 37°C, 2×10^5 cells in 100 μl were added to each well and cultured for 1 day. The infected cells were washed twice with PBS, resuspended in 200 μl fresh medium, and cultured in a new 96-well plate. Viral infection was examined 4 days post-inoculation by intracellular staining of p27, as described above for the analysis of viral infectivity. Infectivity was determined in duplicate and the average value was used for the analysis of neutralization.

All neutralizing assays were performed at least twice and the representative results are shown.


WESTERN BLOTTING ANALYSIS OF VIRAL PROTEINS

Cells and supernatants were collected from six-well plate 2 days after transfection of 293T cells with infectious molecular clones, as previously described (Yuste et al., 2005). Supernatants were filtered (0.45 μm) and clarified by centrifugation for 10 min at 3,000 rpm. The clarified supernatants were centrifuged at 13,200 rpm for 90 min at 4°C, and the viral pellets were resuspended in 1 ml PBS and centrifuged again. Pellets were then dissolved in 80 μl sample buffer [62.5 mM Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate (SDS), 25% glycerol, 5% 2-mercaptoethanol, 0.01% bromophenol blue]. Cells were washed with PBS and lysed in 300 μl sample buffer. Samples of virions and cell lysates were boiled for 5 min, and the proteins were separated by SDS-polyacrylamide gel electrophoresis using SuperSep Ace 5–20% (Wako Pure Chemical Industries, Osaka, Japan). Proteins were transferred to an Immun-Blot PVDF Membrane (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was blocked with 5% skim milk TBS-T (Tris-buffered saline containing 0.1% Tween 20) for 1 h at RT, and then washed three times with TBS-T. For the detection of gp120, the membrane was incubated overnight at 4°C with 1 $\mu\text{g/ml}$ M318T (Matsumi et al., 1995) in 5% skim milk TBS-T. After washing three times with TBS-T, the membrane was incubated with anti-mouse immunoglobulin G (IgG) peroxidase (1:4,000, Santa Cruz Biotechnology) for 1 h at RT. The membrane was washed three times with TBS-T and once with TBS, and then TMB solution (KPL, Gaithersburg, MD, USA) was added to develop color. Viral proteins gp41 and p26 were similarly examined using crude supernatants from bacterial culture producing B408 and B450 (Kuwata et al., 2011), which were mixed with the same amount of 5% skim milk TBS-T. The membrane was incubated with anti-HA-HRP antibody (1:1,000; Roche Molecular Biochemicals) and Chemi-Lumi One L (Nacalai Tesque, Kyoto, Japan), and viral proteins were visualized using ImageQuant LAS 4000 (GE Healthcare, Piscataway, NJ, USA)

RESULTS

EVOLUTION OF VIRUSES DURING PASSAGE UNDER THE PRESSURE OF Fab-B404

To select for variants resistant to MAb B404, an antibody that targets a conformational epitope comprising the gp120 V3 and V4 loops, we passaged SIVmac316 that possesses a full-length gp41 in PM1/CCR5 cells in the presence of increasing concentrations of Fab-B404. The virus recovered at passage 26 (P26B404) was resistant to neutralization by B404 (V3/V4) and other antibodies, MAbs K8 (CD4i) and M318T (V2), that target epitopes other than that recognized by B404 (Kuwata et al., 2013). The region covering the whole *env* gene were amplified by PCR and cloned from viruses at passage 8, 17, 20, 23, and 26. The nucleotide sequences were phylogenetically analyzed to show the evolution of B404-resistant variants (Figure 1). The first major mutation was a change from glutamine (CAG) to a stop codon (TAG) at 733rd amino acid residue of Env. The Q733stop substitution in the gp41 cytoplasmic domain was observed in 12 of 14 clones at passage 8 and in all clones thereafter. Another stop codon (W782stop) was the second



major mutation, which was detected after 17 passages. Substitutions V17L in the signal peptide and E176K in the V2 loop emerged after 20 and 23 passages, respectively, although the E176K substitution was also observed in P26C, control viruses after 26 passages in the absence of B404 (Table 1). In addition to these substitutions, most of clones acquired the F277V substitution in the late stage of evolution, except for one group at passage 26 which has the N295S substitution (see Figure 1, group 26II). Group 26II was clearly distinguished from group 26I by amino acid substitutions, such as T136M, N295S, and D571M/E (Table 1), suggesting two lineages of variants in P26B404.

These results demonstrated that the first step in acquiring resistance to B404 was the truncation of gp41. Although substitutions

in gp120, represented by F277V, might contribute to the resistance to a high concentration of B404, 20 passages were required for the emergence of these substitutions.

TRUNCATION OF gp41 CONFERRED RESISTANCE TO ANTIBODY-MEDIATED NEUTRALIZATION

To analyze effect of substitutions in B404-resistant variants on resistance to neutralization, recombinant viruses were constructed (Figure 2). The env region of SIVmac316 was replaced by that of P26B404 clone 26, which had substitutions typical to the P26I group. The resultant molecular clones SS, SN, and NS had substitutions in the entire env region, gp120 and gp41 from P26B404I, respectively. SS and NS were predicted to have a truncated gp41 with no other mutation in gp41, because the Q733stop substitution was the first substitution in gp41. Point mutants with substitutions F277V and N295S, which were representative mutations at late passages, were also constructed by PCR mutagenesis.

These mutant viruses were examined for their sensitivity to neutralization by three MAbs B404 (V3/V4 conformational), K8 (CD4i), and M318T (V2). The neutralization of SS that contain the entire env region from P26B404I was similar to those of P26B404, indicating that the env region is responsible for the

Table 1 | Frequency* of amino acid substitutions in Env clones from B404-resistant variants after 26 passages.

Substitution	Region	P26B404		P26C
		I	II	
	gp120	(n = 22)	(n = 8)	(n = 14)
V17L	Signal peptide	100%	100%	0.0%
G62S	C1	0.0%	0.0%	21.4%
M67V/L/T	C1	4.5%	0.0%	21.4%
A68T	C1	0.0%	0.0%	92.9%
T136M	V1	4.5%	87.5%	0.0%
T137I	V1	0.0%	0.0%	14.3%
K141E/R	V1	0.0%	12.5%	7.1%
E176K	V2	90.9%	12.5%	35.7%
F277V	C2	100%	0.0%	0.0%
N295S	C2	0.0%	100%	0.0%
Q341H	V3	13.6%	12.5%	14.3%
D374N	C3	0.0%	0.0%	28.6%
K403R	V4	0.0%	12.5%	7.1%
W441R	C4	4.5%	0.0%	7.1%
	gp41	(n = 10)	(n = 2)	(n = 7)
F528S/L	Extracellular	20.0%	0.0%	0.0%
D571M/E	Extracellular	10.0%	100%	0.0%
Q733stop	Cytoplasmic	100%	100%	0.0%
W762stop	Cytoplasmic	100%	0.0%	0.0%
W782stop	Cytoplasmic	100%	0.0%	0.0%
A833T	Cytoplasmic	90.0%	0.0%	0.0%
R839K	Cytoplasmic	0.0%	0.0%	57.1%
R861K	Cytoplasmic	100%	100%	0.0%

*Percentages of substitutions in populations P26B404 and P26C, which were obtained after 26 passages in the presence and absence of B404, respectively, are shown. The P26B404 population is separated into two subpopulations according to the phylogenetic analysis in Figure 1. All the substitutions that are observed in more than one clone are shown here. Boldface indicates substitutions dominant (>50%) in each population. The numbers of clones analyzed for the gp120 and gp41 regions are shown in parentheses.




FIGURE 2 | Construction of infectious SIV clones with B404-resistant mutations. The open reading frames of the SIV genome are shown along with the Env substitutions in the B404-resistant variant typical to P26B404I. Full-length SIV clones were constructed from parental SIVmac316 by replacing the env region with that of the B404-resistant variant (blue) using SphI, NheI, and SacI sites. The resultant virus SS contains all of the Env substitutions present in P26B404I. Viruses SN and NS contain substitutions in gp120 and gp41, respectively. Point mutants F277V and N295S were constructed by inserting the substitutions F277V and N295S into SIVmac316, respectively.